Table 2. Obesity-related factors according to clinicopathological features in colorectal cancers patients.

		Adiponectin (ng ml–1)			IGF-1 (ng ml–1)			Insulin (μU ml–1)			C-peptide (μg ml–1)			BMI
	Total N	Mean	Standard deviation	P-value	Mean	Standard deviation	P-value	Mean	Standard deviation	P-value	Mean	Standard deviation	P-value	Mean	Standard deviation	P-value
Gender (N total=344)
Female	171	10213	6514	<0.001a	82.04	30.56	<0.001a	12.94	23.46	0.106a	4.41	3.51	0.128a	27.45	6.05	0.745a
Male	173	7037	5107		104.15	36.83		17.07	23.82		5.01	3.82		27.64	4.64
Age groups (N total=344)
31–50	13	6668	5822		99.76	41.46		24.18	32.41		4.26	2.96		28.87	6.03
51–60	28	6989	4474	0.003b	96.9	28.78	0.076b	17.7	20.69	0.612b	4.27	3.68	0.444b	29.36	4.12	0.003b
61–70	102	7812	5739	0.005c	99.35	31.06	0.095c	14.45	21.99	0.108c	4.35	3.39	0.231c	28.57	6.07	0.012c
71–80	146	8671	5486		91.21	36.09		14.77	24.94		4.81	3.84		27.2	5.13
81–91	55	11250	7884		83.39	41.76		13.2	22.74		5.42	3.88		25.44	4.33
AJCC (N total=343)
I	69	9965	6382		94.96	37.14		13	16.35		4.83	3.24		27.37	7.36
IIA	115	8588	5922		93.16	37.25		14.41	21.69		4.39	3.47		27.92	4.64
IIB	29	7289	5097	0.148b	102.91	31.73	0.699b	19.57	30.36	0.873b	5.98	4.38	0.586b	27.71	5.48	0.956b
IIIA	9	6945	6117	0.082c	86.4	19.76	0.208c	13.1	18.17	0.93c	4.06	3.12	0.775c	26.7	4.68	0.892c
IIIB	71	8322	5607		90.72	33.58		17.3	30.78		4.7	3.84		27.28	5.19
IIIC	36	9338	7687		92.93	37.94		14.18	23.55		4.71	4.32		27.04	3.84
IV	14	5672	3448		84.42	33.62		13.22	19.87		4.7	3.69		28.35	5.29
T stage (N total=342)
T1	28	9455	6342		94.68	35.45		17.08	17.81		5.43	3.83		28.3	5.49
T2	59	8927	6292	0.811b	93.52	35.73	0.989b	11.16	16.02	0.534b	4.35	2.77	0.654b	27.05	7.71	0.443b
T3	182	8583	6091	0.336c	92.79	36.14	0.735c	15.36	24.51	0.842c	4.73	3.81	0.463c	27.9	4.7	0.374c
T4	73	8243	5791		92.18	34.01		16.77	28.75		4.69	3.99		26.89	4.84
N stage (N total=337)
N0	214	8918	5997	0.449b	94.63	36.66	0.577b	14.62	21.52	0.703b	4.74	3.56	0.985b	27.73	5.75	0.736b
N1	79	7907	5467	0.82c	90	32.53	0.577c	16.84	30	0.776c	4.66	3.9	0.925c	27.29	5.32	0.539c
N2	44	8666	7258		91.34	35.39		13.47	21.75		4.68	4.07		27.16	3.77
Grade (N total=245)
1	8	10699	8464	0.563b	89.7	25.03	0.207b	10.39	13.76	0.231b	3.62	2.14	0.463b	23.97	5.18	0.071b
2	176	9105	5645	0.998c	96.81	36.67	0.812c	17.11	26.21	0.691c	4.92	3.94	0.394c	27.73	5.6	0.249c
3	58	8670	5676		87.13	39.43		11.57	14.86		4.57	2.95		26.84	4.33
Lymph/vascular invasion (N total=337)
No	236	8724	6099	0.938a	94.21	34.52	0.373a	14.08	21.87	0.505a	4.69	3.54	0.977a	27.56	5.55	0.71a
Yes	101	8668	6048		90.44	37.71		15.92	26		4.68	3.96		27.31	4.95
Perineural invasion (N total=159)
No	135	7023	5870	0.027a	94.69	32.84	0.609a	13.05	22.93	0.94a	4.18	3.34	0.928a	28.06	5.44	0.887a
Yes	17	5099	2755		90.37	32.46		12.61	18.35		4.1	2.59		27.85	6.76
Necrosis (N total=180)
No	142	9645	5574	0.351a	94.38	38.89	0.77a	16.26	22.53	0.915a	5.08	3.91	0.81a	27.64	4.82	0.918a
Yes	38	8707	5152		92.34	34.39		15.81	27.05		4.91	4.19		27.54	5.81
Lymphocytic infiltrate (N total=267)
No	92	7527	4346		95.01	37.05	0.617b	14.06	25.53	0.62b	4.03	3.13	0.234b	27.46	4.7
1	112	9838	5737	0.014b	91.17	33.96	0.923c	16.37	24.45	0.605c	5.06	3.93	0.907c	27.27	5.85	0.928b
2	49	9638	6135	0.074c	87.69	33.65		18.19	26.79		4.72	3.82		27.05	4.94	0.521c
3	14	10497	8107		97.15	32.16		9.67	16.24		4.27	3.26		26.46	5.43

Abbreviations: AJCC=American Joint Committee on Cancer; ANOVA=analysis of variance; BMI=body mass index; IGF-1=insulin-like growth factor-1.

^aIndependent-samples t-test.

^bOne-way ANOVA.

^cTest for linear trend.